Navigation Links
Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers
Date:4/8/2009

LA JOLLA, Calif., April 8 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has agreed to collaborate with BG Medicine (BGM) in its Phase 2 clinical safety trial with CDP-1050 in heart failure patients.

In this collaboration, BGM will measure levels of Galectin-3 in patients enrolled in the study. Galectin-3 is a biomarker for cardiac remodeling associated with advanced stages of heart failure.

CDP-1050 is being developed as a new therapeutic modality in the management of heart failure. It targets the redox-nitiric oxide imbalance, which is increasingly recognized as a major factor in poor myocardial contractile efficiency, the hallmark manifestation of this disorder.

About Heart Failure

Heart failure, a condition characterized by the inability of the heart to effectively pump blood as well as by fluid accumulation in the lungs and other tissues, is suffered by an estimated five million Americans and is responsible for 300,000 deaths in the U.S. annually, according to the National Heart, Lung and Blood Institute. It is the single largest Medicare expense, at a cost of $33.2 billion each year. The five-year mortality rate with heart failure can be as high as fifty (50) percent.

About CDP-1050

CDP-1050 is an investigational drug candidate for the treatment of heart failure. The drug is designed to correct the nitric oxide and redox imbalance in the failing heart and the cardiovascular system. CDP-1050 has a dual mechanism of action; it inhibits the production of excessive reactive oxygen radicals and restores nitric oxide to physiologic levels. The primary therapeutic target is the ryanodine receptor, the main ion channel in the heart that supplies the calcium necessary for the heart to contract. CDP-1050 is expected to enter a Phase 2 clinical trial.

About Cordex Pharma, Inc.

Cordex is a s
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cordex Pharma Sets Fourth Quarter 2008 Program Update Call
2. Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace
3. Cordex Pharma Files ATPace Formulation Patent
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... Le Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, ... the April issue of Nature Reviews Microbiology ... Dr. McCullers, a world-renowned infectious disease specialist, ... the University of Tennessee Health Science Center, analyzed ... 1918, 1957 and 1968 pandemics, as well as ...
(Date:4/17/2014)... 17, 2014U.S. military personnel who served in Iraq ... traumatic brain injury (TBI) were compared to military ... medical reasons. Differences in measures of overall disability, ... after injury are reported in an article in ... from Mary Ann Liebert, Inc., publishers. The article ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2
... at $7.5 Million in 2008, OTTAWA, ... yesterday,s Natural Nutrition press release is, http://www.naturalnutritioninc.com ... Inc., (OTC Bulletin Board: NNTN), http://www.naturalnutritioninc.com ... by adding state-of-the-art equipment to produce,sheeted protein ...
... of Critical and Fatal Implications of ... Diagnosis of Carbon Monoxide Poisoning, IRVINE, Calif., Nov. ... Motion and Low Perfusion pulse,oximetry, today announced the National ... its members advocating carbon monoxide,screenings for patients presenting with ...
... Inc.,(Nasdaq: RGDX ), a company focused on ... announced it will release its third,quarter and nine-month ... November 14, 2007. About Response Genetics, Inc. ... the research and,development of pharmacogenomic cancer diagnostic tests ...
... EMPLOYERS(R) (NYSE: EIG ),a leading ... a,new partnership with the California Restaurant Association ... compensation insurance with a,special CRA membership discount. ... http://www.newscom.com/cgi-bin/prnh/20061030/LAM128LOGO ) "We are enthusiastic ...
... DATA ), a technology and services company focused ... reported its,operating results for the third quarter and first ... ended September 30, 2007, revenue decreased 52% to,$2,116,000, and ... $(0.26),per share on a basic and diluted basis. These ...
... - Companies to Focus Resources on Partnership to Develop Rapid ... Tests for Healthcare-Associated Infections -, ... today that 3M has informed the Company it no longer ... for the,food testing industry. The companies expect to formally terminate ...
Cached Medicine News:Health News:Corrected & Replaced - Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line 2Health News:National Association of EMS Educators (NAEMSE) Recommends Screening for Carbon Monoxide Poisoning 2Health News:National Association of EMS Educators (NAEMSE) Recommends Screening for Carbon Monoxide Poisoning 3Health News:Response Genetics to Announce Third Quarter 2007 Financial Results on Wednesday, November 14, 2007 2Health News:California Restaurant Association Chooses EMPLOYERS(R) as its New Provider of Choice for Members' Workers' Compensation Insurance Needs 2Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 2Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 3Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 4Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 5Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 6Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 7Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 8Health News:3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration 2Health News:3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration 3
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... For years, homecare equipment providers have cited the many ramifications ... of power wheelchairs for beneficiaries.  It is the root cause of ... and it restricts access to power wheelchairs for patients.  But rarely, ... , , ...
... July 16 Human erythropoietin (EPO) is a potent ... spinal cord injury, and Parkinson,s disease. However, EPO drug development ... the blood-brain barrier (BBB). In acute stroke or brain injury, ... insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals ...
Cached Medicine Technology:Physician Outraged by Medicare Power Wheelchair Documentation Policy 2Physician Outraged by Medicare Power Wheelchair Documentation Policy 3Physician Outraged by Medicare Power Wheelchair Documentation Policy 4ArmaGenĀ® Re-engineers Erythropoietin for Brain Penetration 2
SCD Sequential Compression System Intermittent Pneumatic Compression...
Comfor™ Cast Boot - Rocker Sole - Closed Toe...
... A new cast boot specially lasted ... a double rocker sole for easy ... around a narrow last so it ... cast boots, and with our stretchable ...
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
Medicine Products: